Yesterday’s Wall Street Journal has an interesting article about the FDA’s off-label promotion ban being “in some jeopardy” after the Supreme Court’s Sorrell decision, and pointing to the Caronia case, to be decided “within weeks,” as the leading example of possible First Amendment scrutiny.  Well, you heard it here first.  We pointed out this implication of Sorrell back in June, the day that the Supreme Court decided the case.  We’ve been following Caronia even longer. Glad to see the mainstream media waking up, that the government ability to monetize (to the tune of over $8 billion, according to the article) its First Amendment violations may be drawing to a long-overdue close.